Systematic Screening of a Glycolysis-Targeting Small-Molecule Library Identifies Novel Inhibitors of Fungal Morphogenesis in Candida albicans

Abstract Fungal infections are an increasing global health concern, with Candida albicans emerging as a leading cause of mucosal and life-threatening systemic infections. C. albicans relies on yeast-to-hyphae transition, to establish systemic infections in the host. Our recent work demonstrated that glycolysis is a key regulator of hyphal differentiation in C. albicans. Leveraging this knowledge, we screened a small-molecule compound library containing glycolysis inhibitors for their ability to block fungal morphogenesis and identified multiple small molecules that robustly block hyphal differentiation without compromising overall growth. Among these, two compounds (PKM2-IN-6 and NPD10084, both originally identified as modulators of human pyruvate kinase M2 (Pkm2) activity) emerged as the most potent inhibitors of fungal morphogenesis, significantly attenuating hyphal differentiation, in multiple filamentation-inducing conditions. Comparative RNA-Seq analysis revealed significant perturbation of glycolysis following PKM2-IN-6 treatment, while molecular docking analysis predicted that these compounds bind to specific pockets of pyruvate kinase in C. albicans. Interestingly, PKM2-IN-6 treatment resulted in the repression of multiple genes associated with fungal morphogenesis, biofilm formation, and virulence. These transcriptional changes were accompanied by a significant reduction in biofilm formation and increased sensitivity to conventional antifungal drugs, including amphotericin B and fluconazole, in the presence of both compounds, PKM2-IN-6 and NPD10084. Furthermore, administration of PKM2-IN-6 significantly improved the survival of mice in a murine model of systemic candidiasis underscoring the in vivo efficacy of this compound. Collectively, our study has identified novel small molecules that target fungal morphogenesis and virulence in C. albicans, establishing inhibition of glycolysis as a promising antifungal strategy.

Authors

Institutions

Publication Details

Journal
ACS Infectious Diseases
Published
2026-11-16
DOI
https://doi.org/10.1021/acsinfecdis.6c00738
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Systematic Screening of a Glycolysis-Targeting Small-Molecule Library Identifies Novel Inhibitors of Fungal Morphogenesis in Candida albicans

Yogita Martoliya, Sriram Varahan, Shailendra Asthana, Dhrumi Shah et al.
1 links
ACS Infectious Diseases
Antifungal resistance and susceptibility
article

Systematic Screening of a Glycolysis-Targeting Small-Molecule Library Identifies Novel Inhibitors of Fungal Morphogenesis in Candida albicans

Yogita Martoliya, Sriram Varahan, Shailendra Asthana, Dhrumi Shah, Sudharsan Mathivathanan, Ashish Shrivastava
article en

Abstract

Abstract Fungal infections are an increasing global health concern, with Candida albicans emerging as a leading cause of mucosal and life-threatening systemic infections. C. albicans relies on yeast-to-hyphae transition, to establish systemic infections in the host. Our recent work demonstrated that glycolysis is a key regulator of hyphal differentiation in C. albicans. Leveraging this knowledge, we screened a small-molecule compound library containing glycolysis inhibitors for their ability to block fungal morphogenesis and identified multiple small molecules that robustly block hyphal differentiation without compromising overall growth. Among these, two compounds (PKM2-IN-6 and NPD10084, both originally identified as modulators of human pyruvate kinase M2 (Pkm2) activity) emerged as the most potent inhibitors of fungal morphogenesis, significantly attenuating hyphal differentiation, in multiple filamentation-inducing conditions. Comparative RNA-Seq analysis revealed significant perturbation of glycolysis following PKM2-IN-6 treatment, while molecular docking analysis predicted that these compounds bind to specific pockets of pyruvate kinase in C. albicans. Interestingly, PKM2-IN-6 treatment resulted in the repression of multiple genes associated with fungal morphogenesis, biofilm formation, and virulence. These transcriptional changes were accompanied by a significant reduction in biofilm formation and increased sensitivity to conventional antifungal drugs, including amphotericin B and fluconazole, in the presence of both compounds, PKM2-IN-6 and NPD10084. Furthermore, administration of PKM2-IN-6 significantly improved the survival of mice in a murine model of systemic candidiasis underscoring the in vivo efficacy of this compound. Collectively, our study has identified novel small molecules that target fungal morphogenesis and virulence in C. albicans, establishing inhibition of glycolysis as a promising antifungal strategy.

ACS Infectious Diseases
Centre for Cellular and Molecular Biology (IN), Translational Health Science and Technology Institute (IN), Academy of Scientific and Innovative Research (IN)
Department of Biotechnology, Ministry of Science and Technology, India, Indian Council of Medical Research, Science and Engineering Research Board
Good health and well-being
Antifungal resistance and susceptibility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon